Akebia Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that on November 12, 2026, the company entered into a senior secured term loan facility of up to $140.0 million with Symbiotic Capital Opportunities Holding, L.P. as lender and Symbiotic Capital Agency LLC as administrative and collateral agent.

Key Highlights

  • Facility size: Up to $140.0 million in aggregate principal, comprising an initial tranche of $60.0 million funded at closing and discretionary tranches of up to $80.0 million.
  • Net proceeds: Approximately $58.6 million from the Initial Loan, after deducting estimated debt issuance costs, fees, and expenses.
  • Prior debt repaid: On the closing date, the company repaid in full its prior $55.0 million term loan with Kreos, including customary termination fees and other expenses.
  • Interest rate: Variable annual rate equal to the greater of 11.5% or the Wall Street Journal prime rate plus 4.5%, subject to a maximum of 15.0% per annum.
  • Maturity: November 12, 2031, with no scheduled amortization; a 3.25% exit fee applies on any principal repayment or prepayment.
  • Warrants issued: 3,441,352 shares of common stock at an exercise price of $0.6974 per share, exercisable until November 12, 2033, with a 9.99% beneficial ownership cap per Warrant Holder.
  • Financial covenant: When Qualified Cash is at or below $40.0 million, the company must maintain at least $15.0 million of Qualified Cash and meet minimum net revenue thresholds, commencing with the quarter ending December 31, 2026.

Akebia Replaces Kreos Debt with Symbiotic Facility and Issues Warrants

According to the filing, Akebia Therapeutics (NASDAQ:AKBA) closed the Loan and Security Agreement on November 12, 2026, with Symbiotic Capital Opportunities Holding, L.P. as the lead lender and Symbiotic Capital Agency LLC serving as both administrative agent and collateral agent. The Term Loan Facility carries a five-year term maturing November 12, 2031, and bears interest at a variable rate floored at 11.5% or the prime rate plus 4.5%, whichever is greater, capped at 15.0% per annum. The filing notes that upon an event of default, the applicable rate increases by an additional 4.0% per annum.

The company disclosed that net proceeds of approximately $58.6 million from the $60.0 million Initial Loan were used primarily to repay the existing $55.0 million Kreos term loan in full, along with associated termination fees. The filing states that all obligations are unconditionally guaranteed by existing and future domestic subsidiaries and secured by a first-priority security interest in substantially all assets of the loan parties. Voluntary or mandatory prepayment prior to November 12, 2030 is subject to a prepayment premium of 1.0% to 3.0% of the amount prepaid, and prepayments on or before August 12, 2029 also require payment of interest that would have accrued through August 12, 2029. A 3.25% exit fee applies on all principal repayments or prepayments.

As part of the transaction, the company issued warrants to affiliates of the lenders, Symbiotic Capital EO Holding, L.P. and Symbiotic Capital EO Holding II, L.P., to purchase a total of 3,441,352 shares of common stock at $0.6974 per share. The filing notes that upon funding of any Discretionary Tranche Term Loan, warrants automatically become exercisable for additional shares equal to 4.00% of such tranche's principal divided by a price based on the 30-trading-day volume-weighted average price preceding each funding date. The warrants were offered pursuant to the Section 4(a)(2) exemption under the Securities Act and were not registered.

What Was Disclosed

Akebia Therapeutics disclosed entry into a $140.0 million senior secured term loan with Symbiotic Capital on November 12, 2026, the concurrent repayment of a prior Kreos facility, associated warrant issuances, interest rate terms, prepayment premiums, and financial covenants tied to Qualified Cash and net revenue from Vafseo (vadadustat).